What changed this week
Patterns across the week's 93 stories; each point names the stories it rests on.
- Personalized vaccine results diverged by cancer type: melanoma recurrence fell, while the pancreatic vaccine missed its main goal, so vaccine programs need evidence for each disease.Stories 4, 12
- Shorter or simpler care is gaining support through a lower-toxicity bowel cancer schedule, shorter prostate radiation, portable ultrasound triage and financial navigation, reinforcing the value of access services.Stories 5, 60, 87, 88
- Drug combinations show sharply different results across cancers, so the company should judge each regimen by disease-specific evidence rather than assume benefits transfer between tumors.Stories 1, 2, 7, 51
- Radioligand care is moving into established use, while engineered T cells show early human activity but serious delivery risks in animal models, supporting staged investment.Stories 11, 44, 62
Clinical trials
- Camrelizumab regimen improved event-free survival in rectal cancerStory 3
- A shorter drug schedule matched survival in metastatic bowel cancerStory 5
- Cisplatin and gemcitabine did not beat capecitabine for biliary tract cancerStory 6
- Eicosapentaenoic acid linked to longer survival after colorectal cancer liver surgeryStory 16
- Abiraterone improved long-term survival in metastatic prostate cancerStory 17
- Tarlatamab helped people with small-cell lung cancer live longerStory 33
- Ivonescimab combination improves survival in advanced biliary tract cancerStory 35
- Durvalumab and olaparib prolonged survival in advanced endometrial cancerStory 37
- Pembrolizumab added no benefit in early non-small cell lung cancerStory 51
- Darovasertib and crizotinib shrank metastatic uveal melanomaStory 53
- Tarlatamab plus durvalumab extended survival in small cell lung cancerStory 69
- Benmelstobart improved lung cancer outcomes after chemoradiotherapyStory 70
- Apalutamide and hormone therapy improved outcomes in prostate cancer surgery studyStory 72
- Methylphenidate reduced fatigue in people with blood cancersStory 86
- Guideline backs shorter radiation for localized prostate cancerStory 87
Precision oncology
- Nivolumab combination did not improve outcomes in bladder cancerStory 1
- Nivolumab and relatlimab improved long-term outcomes in advanced melanomaStory 2
- Adding relatlimab did not improve results in non-small cell lung cancerStory 7
- FDA approves talazoparib with enzalutamide for prostate cancerStory 13
- Radiation improved disease control in non-small cell lung cancerStory 36
- Divarasib improved survival in advanced non-small cell lung cancerStory 49
- Machine learning improved risk prediction for multiple cancersStory 54
- Expert review clarified diagnoses of ambiguous skin melanoma tumorsStory 55
- Blood markers predicted outcomes in metastatic prostate cancerStory 68
- Focal radiation controlled recurrent prostate cancer in trialStory 73
- Targeting DKK1 did not significantly change outcomes in metastatic colorectal cancerStory 84
Antibody-drug conjugates
- Trial tests risvutatug rezetecan for osteosarcomaStory 18
- Sacituzumab tirumotecan improved survival in triple-negative breast cancerStory 31
- Two drugs improved survival in stomach cancerStory 34
- Sacituzumab tirumotecan improved survival in advanced womb cancerStory 50
- Trastuzumab deruxtecan had low response rates in early breast cancerStory 71
- Study of Trastuzumab Deruxtecan in Combination With Stereotactic Radiosurgery in Patients With HER2-Positive Metastatic Breast Cancer and First Diagnosis of Brain Metastases (HERBRAIN)Story 78
- Becotatug Vedotin Plus Gemcitabine and a PD-1 Inhibitor in Recurrent or Metastatic Nasopharyngeal CarcinomaStory 79
- Selpercatinib improved outcomes in advanced medullary thyroid cancerStory 82
- Drug combination showed responses in high-risk bladder cancerStory 83
- AI model predicted drug responses in triple-negative breast cancerStory 85
- Low-Dose Apatinib Plus Chemotherapy in ADC-Pretreated HER2-Positive and HER2-Low Advanced Breast CancerStory 92
Cancer vaccines
- Vaccine trial misses its main goal in pancreatic cancerStory 4
- Personalized vaccine cut recurrence risk in melanoma after surgeryStory 12
- Personalized vaccine cut recurrence risk in melanoma trialStory 14
- Intismeran and pembrolizumab cut recurrence risk in melanomaStory 15
- Personalized vaccine cut recurrence risk in high-risk melanomaStory 23
- Intismeran autogene cut melanoma recurrence risk after surgeryStory 24
- Personalized vaccine cut recurrence risk in melanoma trialStory 25
- TMV Vaccine Alone or With Toripalimab-tpzi for Recurrent Head and Neck Squamous Cell CarcinomaStory 42
- Lupus research finds immune cells respond to new peptidesStory 61
Cell and gene therapy
- Time-limited Treatment With Avatrombopag Pre- and Post-CAR T-cell Therapy to Prevent Post-CAR T-cell CytopeniasStory 22
- Pancreatic cancer precursors have a different surrounding environmentStory 32
- The METAMAX Study: MT027 Allogeneic CAR-T for Brain Metastases From Advanced Solid TumorsStory 41
- Lifileucel and pembrolizumab shrank advanced melanoma tumorsStory 52
- A Study of SRN-101 Gene Therapy in Adults With Recurrent High-Grade Glioma (ALERT-1)Story 59
India access
- Entering pharma drug discovery presents an opportunity to apply scientific capabilities to a new set of health challengesStory 29
- FLuorescent Angiography in REduction of Anastomotic Leak in Rectal Cancer SurgeryStory 48
- Portable ultrasound cut referrals for women assessed for breast cancerStory 60
- Use of Portable Ultrasound by Nonradiologists to Triage Women With Abnormal Clinical Breast Examination Findings: A Prospective Study in IndiaStory 66
- MCADDI 2026 brings together drug discovery experts at University of HyderabadStory 67
Solid-tumor CAR-T
Gene therapy
Cancer-care delivery
Radioligands
Head and neck cancer
Other
- A randomized Phase 1 study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab versus trifluridine-tipiracil with bevacizumab in patients with metastatic colorectal cancerStory 8
- LM103, an autologous tumor-infiltrating lymphocyte monotherapy, in patients with advanced melanoma resistant to standard therapyStory 9
- CD8 T-cell exhaustion linked with CAR T-cell failure can be mitigated by a non-alpha IL2 receptor agonistStory 10
- Molecular Underpinnings and Prevalence of Donor Cell-Derived Hematologic Neoplasms among Spanish Transplantation CentersStory 19
- hnRNPA2B1 sustains antitumor T cell immunity and enhances cancer immunotherapy through IDR-dependent stabilization of chromatin-regulatory transcriptsStory 20
- Patient Sociodemographic Factors Impact the Breast Cancer MicroenvironmentStory 21
- FDA Approves Talazoparib With Enzalutamide for Certain Metastatic HRR-Mutated Prostate CancersStory 26
- A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian CancerStory 27
- Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced non-small cell lung cancer and Other Solid Tumors, Alone and in CombinationStory 28
- ‘VIP culture’ in hospitals can compromise patient safety, equitable care: AIIMS doctorsStory 30
- Hypoxia-inducible CEA-targeted CAR T-cell therapy for relapsed stage IV non-small cell lung cancerStory 38
- Genomic Landscape of Gastroenteropancreatic Neuroendocrine Neoplasms Using Panel SequencingStory 39
- Prospective circulating tumour DNA surveillance in patients with early high-risk hormone receptor positive, HER2-negative breast cancer in the TRAK-ER studyStory 40
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)Story 46
- A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or PancreasStory 47
- Multi-omics reveals evolution from CD7-negative T cell dysregulation to EBV-positive LPD after CD7 CAR-T therapyStory 56
- Tumor-Immune Microenvironment of Early-Onset Colorectal Cancer: Implications for Immune-Based Prevention and TherapyStory 57
- Brain-sensing synNotch-CAR T cells enable precise targeting and clearance of diffuse midline glioma in multiple preclinical modelsStory 58
- A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic non-small cell lung cancer Harboring HER2 Exon 20 MutationsStory 63
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)Story 64
- FGFR Alterations in Bladder Cancer-From Molecular Pathogenesis to Precision OncologyStory 75
- AI for detection of adverse events in the real worldStory 76
- How Is Living in an Ethnic Neighborhood Linked to Cancer Outcomes?Story 77
- AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian CancerStory 80
- Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With OsteosarcomaStory 81
- From TAILORx to OPTIMA: Evolving Evidence for Genomically Guided Chemotherapy in Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast CancerStory 89
- B7-H4‒directed antibody-drug conjugate AZD8205 (puxitatug samrotecan) in patients with advanced/metastatic solid tumors: the Phase 1/2a (BLUESTAR), first-in-human studyStory 90
- Performance of artificial intelligence-assisted cytology and high-risk human papillomavirus testing for cervical cancer screeningStory 91